Applications of Bioengineered 3D Tissue and Tumor Organoids in Drug Development and Precision Medicine: Current and Future
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Over the past decade, advances in biomedical and tissue engineering technologies, such as cell culture techniques, biomaterials, and biofabrication, have driven increasingly widespread use of three-dimensional (3D) cell culture platforms and, subsequently, the use of organoids in a variety of research endeavors. Given the 3D nature of these organoid systems, and the frequent inclusion of extracellular matrix components, these constructs typically have more physiologically accurate cell–cell and cell–matrix interactions than traditional 2D cell cultures. As a result, 3D organoids can serve as better model systems than their 2D counterparts. Moreover, as organoids can be biofabricated from highly functional human cells, they have certain advantages over animal models, being human in nature and more easily manipulated in the laboratory. In this review, we describe such organoid technologies and their deployment in drug development and precision medicine efforts. Organoid technologies are rapidly being developed for these applications and now represent a wide variety of tissue types and diseases. Evidence is emerging that organoids are poised for widespread adoption, not only in academia but also in the pharmaceutical industry and in clinical diagnostic applications, positioning them as indispensable tools in medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reconstituting organ-level lung functions on a chip
Huh, D., Matthews, B. D., Mammoto, A., Montoya-Zavala, M., Hsin, H. Y., & Ingber, D. E. (2010) · Science · doi:10.1126/science.1188302 · Cited by 4,250 · cited 1×
“The vacuum channels could be used to stretch the membrane and exhibit strain on the cells [68].”
Organogenesis in a dish: Modeling development and disease using organoid technologies
Lancaster, M. A., & Knoblich, J. A. (2014) · Science · doi:10.1126/science.1247125 · Cited by 2,931 · cited 1×
“Organoids can be defined as 3D constructs comprising tissue-specific cells with the intention of recapitulating the cellular microenvironment; organoids may also include ECM components or biomaterials to achieve this aim [2].”
The third dimension bridges the gap between cell culture and live tissue
Pampaloni, F., Reynaud, E. G., & Stelzer, E. H. K. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2236 · Cited by 2,817
Hydrogels as extracellular matrix mimics for 3D cell culture
Tibbitt, M. W., & Anseth, K. S. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22361 · Cited by 2,727 · cited 1×
“Common biomaterials for use with organoids include collagen, hyaluronic acid, gelatin, and chitosan [23, 24].”
Drug-induced prolongation of the QT interval
Roden, D. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032426 · Cited by 1,965
Deconstructing the third dimension – how 3D culture microenvironments alter cellular cues
Baker, B. M., & Chen, C. S. (2012) · Journal of Cell Science · doi:10.1242/jcs.079509 · Cited by 1,760
Modeling Tissue Morphogenesis and Cancer in 3D
Yamada, K. M., & Cukierman, E. (2007) · Cell · doi:10.1016/j.cell.2007.08.006 · Cited by 1,751
Organoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
Schwank, G., Koo, B.-K., Sasselli, V., Dekkers, J. F., Heo, I., Demircan, T., Sasaki, N., Boymans, S., Cuppen, E., van der Ent, C. K., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.11.002 · Cited by 1,424
Microscale culture of human liver cells for drug development
Khetani, S. R., & Bhatia, S. N. (2008) · Nature Biotechnology · doi:10.1038/nbt1361 · Cited by 1,219 · cited 3×
“The addition of fibroblasts increased the duration and magnitude of hepatocyte function as measured by mitochondrial metabolism and cytochrome p450 (CYP) activity, demonstrating the importance of cell–cell interaction and the incorporation of a stromal component for physiologic liver function [33].”
Influential
Cited by
Scaffolding Strategies for Tissue Engineering and Regenerative Medicine Applications
Pina, S., Ribeiro, V. P., Marques, C. F., Maia, F. R., Silva, T. H., Reis, R. L., & Oliveira, J. M. (2019) · Materials · doi:10.3390/ma12111824 · Cited by 493
Personalised organs-on-chips: functional testing for precision medicine
van den Berg, A., Mummery, C. L., Passier, R., & van der Meer, A. D. (2019) · Lab on a Chip · doi:10.1039/c8lc00827b · Cited by 270
Drug compound screening in single and integrated multi-organoid body-on-a-chip systems
Skardal, A., Aleman, J., Forsythe, S., Rajan, S., Murphy, S., Devarasetty, M., Pourhabibi Zarandi, N., Nzou, G., Wicks, R., Sadri-Ardekani, H., et al. (2020) · Biofabrication · doi:10.1088/1758-5090/ab6d36 · Cited by 270
Self-citationAleman, J., & Skardal, A. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.26871 · Cited by 160
Self-citationXiang, D., He, A., Zhou, R., Wang, Y., Xiao, X., Gong, T., Kang, W., Lin, X., Wang, X., Consortium11, P.-B. D., et al. (2024) · Theranostics · doi:10.7150/thno.96027 · Cited by 108
Metadata
- Authors
- Devarasetty, M., Mazzocchi, A. R., & Skardal, A.
- Venue
- BioDrugs
- Published
- 2018-01-30
- Volume
- 32
- Issue
- 1
- Pages
- 53-68
- ISSN
- 1172-7039 (ISSN-L)
- 1173-8804
- 1179-190X
- OpenAlex
- W2789608504
- Cited by
- 75
- References
- 41
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Applications of Bioengineered 3D Tissue and Tumor Organoids in Drug Development and Precision Medicine: Current and Future. https://app.cochat.ai/papers/10.1007/s40259-017-0258-x
- The paper
- Devarasetty, M., Mazzocchi, A. R., & Skardal, A. (2018). Applications of Bioengineered 3D Tissue and Tumor Organoids in Drug Development and Precision Medicine: Current and Future. BioDrugs. https://doi.org/10.1007/s40259-017-0258-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.